¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 19

Limitations in predicting PAM50 intrinsic subtype and risk of

relapse score with Ki67 in estrogen receptor-positive HER2-

negative breast cancer

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,9,10,11,12,13,14,15,16,17,18 20,21,22,23,24